Realizing the potential of organoids—an interview with Hans Clevers

Bartfeld, Sina

doi:10.1007/s00109-020-02025-3

Cited by 6 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Am J Bioeth AJOB. 2022 Jan;22(1):54–6 [ 38 ] Bartfeld S. Realizing the potential of organoids-an interview with Hans Clevers. J Mol Med Berl Ger.…”

Section: Resultsmentioning

confidence: 99%

“…Over one-third of the publications ( n = 19) noted that embryoid research could avoid some of the ethical concerns or practical problems associated with human embryo research [ 9 , 21 – 37 , 47 ]. Several scholars also believed that embryoid research could offer an ethical alternative to animal research and reduce reliance on animals ( n = 8) [ 22 , 26 , 30 , 31 , 35 , 38 , 39 , 47 ]. A third potential benefit noted is that embryoid research could improve scientific knowledge in ways that advance human health ( n = 12) [ 9 , 21 , 22 , 24 , 26 , 30 , 36 , 40 – 42 , 45 , 46 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Ethical, legal, regulatory, and policy issues concerning embryoids: a systematic review of the literature

Iltis,

Koster,

Reeves

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

Recent advances in methods to culture pluripotent stem cells to model human development have resulted in entities that increasingly have recapitulated advanced stages of early embryo development. These entities, referred to by numerous terms such as embryoids, are becoming more sophisticated and could resemble human embryos ever more closely as research progresses. This paper reports a systematic review of the ethical, legal, regulatory, and policy questions and concerns found in the literature concerning human embryoid research published from 2016 to 2022. We identified 56 papers that use 53 distinct names or terms to refer to embryoids and four broad categories of ethical, legal, regulatory, or policy considerations in the literature: research justifications/benefits, ethical significance or moral status, permissible use, and regulatory and oversight challenges. Analyzing the full range of issues is a critical step toward fostering more robust ethical, legal, and social implications research in this emerging area and toward developing appropriate oversight.

show abstract

“…Am J Bioeth AJOB. 2022 Jan;22(1):54–6 [ 38 ] Bartfeld S. Realizing the potential of organoids-an interview with Hans Clevers. J Mol Med Berl Ger.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Ethical, legal, regulatory, and policy issues concerning embryoids: a systematic review of the literature

Iltis,

Koster,

Reeves

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…He was a postdoctoral researcher in Hans Clevers’ laboratory and was involved in the initial establishment of “mini-guts” in culture, after which he returned to Keio University (Tokyo, Japan) to focus on digestive tract organoids. The most predominant researchers were from the Clevers’ laboratories, including Sina Bartfeld, Johan H Van es, Marc Van de Wetering, and Huch Meritxell[ 29 - 31 ].…”

Section: Discussionmentioning

confidence: 99%

Bibliometrics analysis based on the Web of Science: Current trends and perspective of gastric organoid during 2010-2023

Jiang,

Jia,

Liu

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

BACKGROUND Three-dimensional organoid culture systems have been established as a robust tool for elucidating mechanisms and performing drug efficacy testing. The use of gastric organoid models holds significant promise for advancing personalized medicine research. However, a comprehensive bibliometric review of this bur-geoning field has not yet been published. AIM To analyze and understand the development, impact, and direction of gastric organoid research using bibliometric methods using data from the Web of Science Core Collection (WoSCC) database. METHODS This analysis encompassed literature pertaining to gastric organoids published between 2010 and 2023, as indexed in the WoSCC. CiteSpace and VOSviewer were used to depict network maps illustrating collaborations among authors, institutions and keywords related to gastric organoid. Citation, co-citation, and burst analysis methodologies were applied to assess the impact and progress of research. RESULTS A total of 656 relevant studies were evaluated. The majority of research was published in gastroenterology-focused journals. Globally, Yana Zavros, Hans Clevers, James M Wells, Sina Bartfeld, and Chen Zheng were the 5 most productive authors, while Hans Clevers, Huch Meritxell, Johan H van Es, Marc Van de Wetering, and Sato Toshiro were the foremost influential scientists in this area. Institutions from the University Medical Center Utrecht, Netherlands Institute for Developmental Biology (Utrecht), and University of Cincinnati (Cincinnati, OH, United States) made the most significant contributions. Currently, gastric organoids are used mainly in studies investigating gastric cancer (GC), Helicobacter pylori -infective gastritis, with a focus on the mechanisms of GC, and drug screening tests. CONCLUSION Key focus areas of research using gastric organoids include unraveling disease mechanisms and enhancing drug screening techniques. Major contributions from renowned academic institutions highlight this field’s dynamic growth.

show abstract

“…89 Additionally, to be able to commercialize organoids, it should be stressed that organoids can add different degrees of value to different parts of the healthcare system and the medical technology development pathway. [104][105][106] However, the donor liver shortage itself is not the only limiting factor for being able to treat all liver patients, as many infrastructural bottlenecks continue to exist as well. Discussing those falls beyond the scope of this overview, but in the end, all remaining bottlenecks are related to economic constraints that hinder the upscaling of treating liver patients by replacing diseased with healthy liver tissue (whether achieved with organoids, constructs, or whole livers)-even if more tissue is available.…”

Section: Outlook and Conclusionmentioning

confidence: 99%

Toward Transplantation of Liver Organoids: From Biology and Ethics to Cost-effective Therapy

et al. 2023

View full text Add to dashboard Cite

Liver disease is a common cause of morbidity and mortality, and many patients would benefit from liver transplantation. However, because of a shortage of suitable donor livers, even of those patients who are placed on the donor liver waiting list, many do not survive the waiting time for transplantation. Therefore, alternative treatments for end-stage liver disease need to be explored. Recent advances in organoid technology might serve as a solution to overcome the donor liver shortage in the future. In this overview, we highlight the potential of organoid technology for cell therapy and tissue engineering approaches. Both organoid-based approaches could be used as treatment for end-stage liver disease patients. Additionally, organoid-based cell therapy can also be used to repair liver grafts ex vivo to increase the supply of transplantable liver tissue. The potential of both approaches to become clinically available is carefully assessed, including their clinical, ethical, and economic implications. We provide insight into what aspects should be considered further to allow alternatives to donor liver transplantation to be successfully clinically implemented.

show abstract

Realizing the potential of organoids—an interview with Hans Clevers

Cited by 6 publications

References 16 publications

Ethical, legal, regulatory, and policy issues concerning embryoids: a systematic review of the literature

Ethical, legal, regulatory, and policy issues concerning embryoids: a systematic review of the literature

Bibliometrics analysis based on the Web of Science: Current trends and perspective of gastric organoid during 2010-2023

Toward Transplantation of Liver Organoids: From Biology and Ethics to Cost-effective Therapy

Contact Info

Product

Resources

About